GNRH1 and peripheral arterial disease: Peripheral arterial disease (PAD) and venous thromboembolism (VTE): GnRH agonist usage was linked to a greater risk of PAD (aHR = 1.16; 95% CI = 1.12-1.21) and VTE (aHR = 1.10; 95% = CI 1.04-1.15).